Pronase
PreclinicalProtein / enzyme
Pronase is one of 64 small molecule programs targeting Colitis. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
93 competitors in Esophageal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Herceptin
RochePhase 3
Keytruda
Merck & Co.Phase 3
Beyfortus
BeiGenePhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Perjeta
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colitis1 trial
Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis
Not yet recruiting·—·N/A·NCT06874673·438 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pronase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details